BC Platforms, founded in 1997 from an MIT Whitehead project spinoff, is in the business of powerful genomic data management and analysis solutions. The company operates a global network of biobanks known as BCRQUEST.COM, which provides genomic and clinical cohort data for pharmaceutical and medical research and development.
BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development in Helsinki, Finland, and sales and marketing in London, Boston, and Vancouver.
Proteus Genomics is a molecular genetics lab, founded in 2015, headquartered in Birmingham, Alabama, specializing in the delivery of precision medicine in a broad spectrum of applications including pharmacogenomics.
Proteus works with clinicians, hospitals, health systems and payors to deliver personalized medicine to a wide range of specialties. In addition to clinical delivery of precision medicine, Proteus is also actively involved in various research projects with pharmaceutical companies, academic institutions and insurance companies.
These projects range from collecting genetic and clinical data in order to give more precise guidance to physicians to identifying biomarkers in drug research projects.
BC Platforms has partnered with Proteus Genomics. In the US, adverse drug events are the fourth leading cause of death, costing the healthcare industry more than $3.5 billion annually. This cost is significantly reduced with genotyping and next generation sequencing technology, which provides genomic context thereby helping to avoid adverse effects.
Additionally, as healthcare in the clinic shifts from a one-for-all approach into personalized care plans, physicians are seeking to develop more targeted therapies for their patients. By combining pharmacology and genomics information through pharmacogenetics, it is possible to provide contextual information that enables clinicians to develop effective, safe medications and doses that are tailored to a patient’s genetic makeup.
“Together, BC Platforms and Proteus Genomics will help advance precision medicine through our streamlined approach to manage data from sequencing machines all the way through to clinical applications. We expect these organized genomics analyses will help create clear, actionable insights to improve patient care and reduce treatment costs.” – Tero Silvola, CEO of BC Platforms
“We are delighted to be collaborating with BC platforms, a leader in the space of genomic data management and analysis. We believe this partnership will play a critical role in continuing to expand the delivery of clinically actionable precision medicine.” – Ben Williams, CEO of Proteus Genomics
Sources:
